Adherence to cervical cancer screening varies by human papillomavirus vaccination status in a high-risk population

Preventive Medicine Reports

Volumn 2, Issue , 2015, Pages 711-716

  Paynter, Christopher A ^a   Van Treeck, Benjamin J ^b   Verdenius, Inge ^c   Lau, Agnes W Y ^d   Dhawan, Twinkle ^e   Lash, Kayla A ^f   Bergamini, Elizabeth A ^g   Ekekezie, Chiazotam N ^h   Hilal, Amna M ⁱ   James, Kristen N ^e   Alongi, Sadie ^a   Harper, Sean M ^j   Bonham, Aaron J ^k   Baumgartner, Kathy B ^j   Baumgartner, Richard N ^j   Harper, Diane M ^j,l,m  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b Mayo School of Graduate Medical Education ^*  (United States)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e JACKSON MEMORIAL HOSPITAL   (United States)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^g SAINT LOUIS UNIVERSITY   (United States)

^h BROWN UNIVERSITY   (United States)

ⁱ Northwell Health   (United States)

^j UNIVERSITY OF LOUISVILLE   (United States)

^k MCMASTER UNIVERSITY   (Canada)

^l University of Louisville School of Medicine   (United States)

^m University of Louisville   (United States)

more..

Author keywords

Cervical cancer; Cervical cancer screening; Compliance; HPV4; Women

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE; ARTICLE; CANCER SCREENING; COHORT ANALYSIS; COMPARATIVE STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 4; MEDICAL EXAMINATION; PATIENT COMPLIANCE; PRENATAL SCREENING; RETROSPECTIVE STUDY; UTERINE CERVIX CANCER; VACCINATION;

EID: 84940828094     PISSN: None     EISSN: 22113355     Source Type: Journal    
DOI: 10.1016/j.pmedr.2015.07.011     Document Type: Article

References (31)

1. Alexander N.M., Harper D.M., Comes J.C., Smith M.S., Heutinck M.A., et al. Intent to participate in future cervical cancer screenings is lower when satisfaction with the decision to be vaccinated is neutral. PLoS One 2014, 9(6):e98665. 10.1371/journal.pone.0098665.
2. American Congress of Obstetricians and Gynecologists Committee Meeting Number 431 Routine pelvic examination and cervical cytology screening. Obstet. Gynecol. 2009, 113:1190-1193.
3. Anhang Price R., Koshiol J., Kobrin S., Tiro J.A. Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine. Vaccine 2011, 29:4238-4243.
4. Baldur-Felskov B., Dehlendorff C., Munk C., Kjaer S.K. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J. Natl. Cancer Inst. 2014 Mar, 106(3):djt460. (Epub 2014 Feb 19.). 10.1093/jnci/djt460.
5. Beer H., Hibbitts S., Brophy S., Rahman M.A., Waller J., Paranjothy S. Does the HPV vaccination programme have implications for cervical screening programmes in the UK?. Vaccine 2014 Apr 1, 32(16):1828-1833. (Epub 2014 Feb 13). 10.1016/j.vaccine.2014.01.087.
6. Benard VB, Thomas CC, King J,Massetti GM,Doria-Rose VP,Saraiya M; Centers for Disease Control and Prevention (CDC). Vital signs: cervical cancer incidence, mortality, and screening - United States, 2007-2012. MMWR Morb Mortal Wkly Rep. 2014 Nov 7;63(44):1004-9. Available at: . htm?s_cid=mm63e1105a1_w. Accessed April 1, 2015. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm63e1105a1.
7. Bowyer H.L., Dodd R.H., Marlow L.A., Waller J. Association between human papillomavirus vaccine status and other cervical cancer risk factors. Vaccine 2014, 32:4310-4316.
8. Budd A.C., Brotherton J.M., Gertig D.M., Chau T., Drennan K.T., Chappeli G., Saville M. Cervical screening rates for women vaccinated against human papillomavirus. Med. J. Aust. 2014, 201:279-282.
9. Centers for Disease Control and Prevention Cancer screening. MMWR 2012, 61:41-45. (Available at: http://www.cdc.gov/nchs/data/hus/2013/084.pdf Accessed April 1, 2015).
10. Committee on Practice Bulletins-Gynecology ACOG practice bulletin number 131: screening for cervical cancer. Obstet. Gynaecol. 2012, 120(5):1222-1238. (http://10.1097/AOG.0b013e318277c92a).
11. Cullen K.A., Stokley S., Markowitz L.E. Uptake of human papillomavirus vaccine among adolescent males and females: immunization information system sentinel sites, 2009-2012. Acad. Pediatr. 2014, 10.1016/j.acap.2014.03.005.
12. de Blasio B.F., Neilson A.R., Klemp M., Skjeldestad F.E. Modeling the impact of screening policy and screening compliance on incidence and mortality of cervical cancer in the post-HPV vaccination era. J. Public Health (Oxf.) 2012, 34:539-547.
13. Drolet M., Boily M.C., Greenaway C., Deeks S.L., Blanchette C., et al. Sociodemographic inequalities in sexual activity and cervical cancer screening: implications for the success of human papillomavirus vaccination. Cancer Epidemiol. Biomark. Prev. 2013, 22:641-652.
14. Freeman HP, Wingrove BK (2005) Excess Cervical Cancer Mortality: A Marker for Low Access to Health Care in Poor Communities. Rockville, MD: National Cancer Institute, Center to Reduce Cancer Health Disparities. NIH Pub. No. 05-5282. Available at: Accessed April 1 2015. http://crchd.cancer.gov/attachments/excess-cervcanmort.pdf.
15. Harper D.M., Nieminen P., Paavonen J., Lehtinen M. Cervical cancer incidence can increase despite HPV vaccination. Lancet Infect. Dis. 2010, 10:594-595.
16. Healthy People 2020. C-15. Increase the proportion of women who receive a cervical cancer screening based on the most recent guidelines. Available at: Accessed April 1, 2015. http://healthypeople.gov/2020/topicsobjectives2020/DataDetails.aspx?hp2020id=C-15.
17. Henderson L., Clements A., Damery S., Wilkinson C., Austoker J., et al. 'A false sense of security'? Understanding the role of the HPV vaccine on future cervical screening behaviour: a qualitative study of UK parents and girls of vaccination age. J. Med. Screen. 2011, 18:41-45.
18. Huh W.K., Ault K.A., Chelmow D., Davey D.D., Goulart R.A., Garcia F.A., Kinney W.K., Massad L.S., Mayeaux E.J., Saslow D., Schiffman M., Wentzensen N., Lawson H.W., Einstein M.H. Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. Gynecol. Oncol. Jan 6 2015, (pii: S0090-8258(14)01577-7). 10.1016/j.ygyno.2014.12.022.
19. IBM Corp. (Released 2011). IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.52. IBM Corp.(2012) Cochran-Armitage test for trend for 2xl tables. [Internet] Available at: =swg21480127 Accessed April 1, 2015. http://www-01.ibm.com/support/docview.wss?uid.
20. (Accessed August 1, 2015). http://www.ncin.org.uk/publications/data_briefings/cervical_incidence:and_screening.
21. Kulasingam S.L., Pagliusi S., Myers E. Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the US. Vaccine 2007, 25:8110-8113.
22. Lewin M.E. Managed Care and the Future Viability of Safety Net Providers Committee on the Changing Market, Institute of Medicine. America's Health Care Safety Net: Intact but Endangered 2000, 1-92. National Academies Press, Washington DC. M.E. Lewin, S. Altman (Eds.).
23. Leyden W.A., Manos M.M., Geiger A.M., Weinmann S., Mouchawar J., et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J. Natl. Cancer Inst. 2005, 97:675-683.
24. Moyer V.A., on behalf of the U.S. Preventive Services Task Force. (2012) Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2012;156:880-891. Internet reference available at: Screening for Cervical Cancer. U.S. Preventive Services Task Force. Accessed April 1, 2015. http://www.uspreventiveservicestaskforce.org/uspstf/uspscerv.htm.
25. Pollock K.G., Kavanagh K., Potts A., Love J., Cuschieri K., et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br. J. Cancer 2014, 111(9):1824-1830.
26. Reddy D.M., Wasserman S.A. Patient anxiety during gynecologic examinations. Behavioral indicators. J. Reprod. Med. 1997, 42:631-636.
27. Sauer A.G., Jemal A., Simard E.P., Fedewa S.A. Differential uptake of recent Papanicolaou testing by HPV vaccination status among young women in the United States, 2008-2013. Cancer Epidemiol. Jun 5 2015, (pii: S1877-7821(15)00101-0). 10.1016/j.canep.2015.05.002.
28. Scarinci I.C., Garcia F.A., Kobetz E., Partridge E.E., Brandt H.M., et al. Cervical cancer prevention: new tools and old barriers. Cancer 2010, 116:2531-2542.
29. Snodgrass R., Naugler C. Use of the Papanicolaou test in women under 25years of age in Southern Alberta. J. Obstet. Gynaecol. Can. 2014, 36:320-323.
30. Solomon D., Davey D., Kurman R., Moriarty A., O'Connor D., et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002, 287. (9-2114).
31. StatSoft, Inc. (2013). STATISTICA (data analysis software system), version 12. Available at: . Accessed April 1, 2015. http://www.statsoft.com.